ARS Pharmaceuticals (SPRY) Competitors

ARS Pharmaceuticals (NASDAQ:SPRY) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, community ranking, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

Do insiders and institutionals hold more shares of SPRY or BPMC?

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 40.1% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Do analysts rate SPRY or BPMC?

ARS Pharmaceuticals currently has a consensus price target of $24.00, suggesting a potential upside of 60.86%. Blueprint Medicines has a consensus price target of $120.00, suggesting a potential upside of 35.06%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe ARS Pharmaceuticals is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.33
Blueprint Medicines	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74

Does the MarketBeat Community favor SPRY or BPMC?

Blueprint Medicines received 507 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 82.61% of users gave ARS Pharmaceuticals an outperform vote while only 67.96% of users gave Blueprint Medicines an outperform vote.

Company	Underperform	Outperform
ARS Pharmaceuticals	Outperform Votes 19 82.61%	Underperform Votes 4 17.39%
Blueprint Medicines	Outperform Votes 526 67.96%	Underperform Votes 248 32.04%

Does the media refer more to SPRY or BPMC?

In the previous week, Blueprint Medicines had 2 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 13 mentions for Blueprint Medicines and 11 mentions for ARS Pharmaceuticals. Blueprint Medicines' average media sentiment score of 1.10 beat ARS Pharmaceuticals' score of 0.48 indicating that Blueprint Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Blueprint Medicines	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is SPRY or BPMC more profitable?

ARS Pharmaceuticals has a net margin of 0.00% compared to Blueprint Medicines' net margin of -56.64%. ARS Pharmaceuticals' return on equity of -19.77% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	N/A	-19.77%	-19.26%
Blueprint Medicines	-56.64%	-157.30%	-34.49%

Which has more risk and volatility, SPRY or BPMC?

ARS Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.

Which has higher earnings and valuation, SPRY or BPMC?

ARS Pharmaceuticals has higher earnings, but lower revenue than Blueprint Medicines. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$30K	47,371.35	-$54.37M	-$0.47	-31.19
Blueprint Medicines	$362.80M	15.45	-$506.98M	-$4.81	-18.60

Summary

ARS Pharmaceuticals beats Blueprint Medicines on 12 of the 18 factors compared between the two stocks.